Franck Bourdeaut

List of Publications by Year
in descending order

96 papers	6,124 citations	109321 35 h-index	74163 75 g-index
112 all docs	112 docs citations	112 times ranked	8338 citing authors

#	Article	IF	Citations
1	A malignant choroid plexus tumour with prevailing immature blastematous elements. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	1
2	Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, 64-78.	2.8	7
3	Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder. American Journal of Human Genetics, 2022, 109, 361-372.	6.2	6
4	High-grade childhood intra-parenchymal brain tumor clustering with ATRT and expanding the cancer spectrum related to inherited SMARCE1 truncating variations. Acta Neuropathologica Communications, 2022, 10, 24.	5.2	0
5	Intraâ€•and extraâ€cranial <scp>BCORâ€ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	3.0	10
6	The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology, 2022, 157, 355-364.	2.9	7
7	High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2156-e2166.	3.6	6
8	Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication. American Journal of Neuroradiology, 2022, 43, 151-156.	2.4	17
9	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 781-794.	3.8	10
10	Immune responses in genomically simple SWI/SNFâ€“deficient cancers. Cancer, 2021, 127, 172-180.	4.1	7
11	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021, 141, 291-301.	7.7	47
12	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	1.9	20
13	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	5.6	53
14	Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?. Neuro-Oncology, 2021, 23, 872-873.	1.2	2
15	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
16	<scp>SMARCA4</scp>â€deficient rhabdoid tumours show intermediate molecular features between <scp>SMARCB1</scp>â€deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. Journal of Pathology, 2021, 255, 1-15.	4.5	14
17	A novel case of cribriform neuroepithelial tumor: A potential diagnostic pitfall in the ventricular system. Pediatric Blood and Cancer, 2021, 68, e29037.	1.5	3
18	A CBF decrease in the left supplementary motor areas: New insight into postoperative pediatric cerebellar mutism syndrome using arterial spin labeling perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3339-3349.	4.3	10

#	Article	IF	Citations
19	Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathologica Communications, 2021, 9, 135.	5.2	21
20	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
21	Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas. Neuro-Oncology, 2020, 22, 128-138.	1.2	22
22	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1â€“2 study. Lancet Oncology, The, 2020, 21, 134-144.	10.7	103
23	The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of â€œCNS tumors with BCOR internal tandem duplicationâ€. Acta Neuropathologica Communications, 2020, 8, 178.	5.2	17
24	Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI. American Journal of Neuroradiology, 2020, 41, 1733-1739.	2.4	8
25	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	1.2	25
26	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	30.7	172
27	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell, 2019, 36, 597-612.e8.	16.8	100
28	Metastatic neuroblastoma in a patient with ROHHAD: A new alert regarding the risk of aggressive malignancies in this rare condition. Pediatric Blood and Cancer, 2019, 66, e27906.	1.5	8
29	SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation. Acta Neuropathologica, 2019, 137, 675-678.	7.7	4
30	Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatric Blood and Cancer, 2019, 66, e27641.	1.5	31
31	Constitutional mismatch repair deficiencyâ€“associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.7	23
32	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. Journal of Medical Genetics, 2019, 56, 53-62.	3.2	40
33	ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors. Acta Neuropathologica, 2019, 137, 175-177.	7.7	43
34	Enrollment in earlyâ€phase clinical trials in pediatric oncology: The experience at Institut Curie. Pediatric Blood and Cancer, 2018, 65, e26916.	1.5	6
35	The extraordinary challenge of treating patients with congenital rhabdoid tumorsâ€”a collaborative European effort. Pediatric Blood and Cancer, 2018, 65, e26999.	1.5	15
36	Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients. European Journal of Human Genetics, 2018, 26, 1217-1221.	2.8	22

#	Article	IF	Citations
37	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. Cancer Cell, 2018, 33, 435-449.e6.	16.8	52
38	Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours. Neuropathology and Applied Neurobiology, 2018, 44, 224-228.	3.2	4
39	MBCL-38. MEDULLOBLASTOMAS ASSOCIATED WITH APC GERMLINE MUTATION: A MULTICENTRIC FRENCH AND BELGIAN REVIEW. Neuro-Oncology, 2018, 20, i125-i125.	1.2	0
40	Genetic predisposition to medulloblastomas: just follow the tumour genome. Lancet Oncology, The, 2018, 19, 722-723.	10.7	2
41	NSRG-05. SAFETY OF ULTRASOUND-INDUCED BLOOD-BRAIN BARRIER OPENING IN PEDIATRIC PATIENTS WITH REFRACTORY SUS-TENTORIAL MALIGNANT BRAIN TUMORS BEFORE CHEMOTHERAPY ADMINISTRATION â€“ THE SONOKID CLINICAL TRIAL. Neuro-Oncology, 2018, 20, i146-i146.	1.2	2
42	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441.	7.0	134
43	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	7.0	139
44	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathologica, 2017, 134, 691-703.	7.7	131
45	Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor. European Journal of Human Genetics, 2017, 25, 1170-1172.	2.8	8
46	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 2017, 23, e98-e106.	7.0	166
47	Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421.	2.5	52
48	ATRT-11. MARKED RESPONSE TO ATEZOLIZUMAB IN AÂPATIENT WITH RHABDOID TUMOR: AÂCASE STUDY FROM THE IMATRIX-ATEZOLIZUMAB TRIAL. Neuro-Oncology, 2017, 19, iv3-iv3.	1.2	8
49	Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. Oncotarget, 2017, 8, 34245-34257.	1.8	13
50	Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature. , 2016, 35, 106-113.		6
51	SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. Pediatric Blood and Cancer, 2016, 63, 568-569.	1.5	12
52	Right to know and right to ignore in paediatric oncogenetics: Identifying biological causes, or seeking for meaning?. European Journal of Cancer, 2016, 63, 53-54.	2.8	0
53	Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Nonâ€Polyalanine Repeat Expansion Mutations. Pediatric Blood and Cancer, 2016, 63, 71-77.	1.5	14
54	The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nature Communications, 2016, 7, 10421.	12.8	92

#	Article	IF	Citations
55	Atypical teratoid/rhabdoid tumorsâ€"current concepts, advances in biology, and potential future therapies. Neuro-Oncology, 2016, 18, 764-778.	1.2	185
56	Embryonal tumors with multilayered rosettes in children: the SFCE experience. Child's Nervous System, 2016, 32, 299-305.	1.1	46
57	Droit de savoir â€" droit Ã lâ€™ignorance, aspects Ã©thiques et psychologiques en oncogÃ©nÃ©tique pÃ©diatrique. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2015, 3, 116-122.	0.1	2
58	Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort. Pediatric Blood and Cancer, 2015, 62, 1733-1738.	1.5	55
59	Fanconi anemia and solid malignancies in childhood: A national retrospective study. Pediatric Blood and Cancer, 2015, 62, 463-470.	1.5	36
60	Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology, 2015, 149, 1017-1029.e3.	1.3	76
61	Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor. Pediatric and Developmental Pathology, 2015, 18, 401-404.	1.0	4
62	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	21.4	252
63	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	22.4	242
64	Water and Electrolyte Disorders at Long-Term Post-Treatment Follow-Up in Paediatric Patients with Suprasellar Tumours Include Unexpected Persistent Cerebral Salt-Wasting Syndrome. Hormone Research in Paediatrics, 2014, 82, 364-371.	1.8	20
65	A SMARCB1-Deficient, Highly Penetrant Brain Tumour Mouse Model Recapitulates Human AT/RT. Cancer Genetics, 2014, 207, 451.	0.4	1
66	Rhabdoid Tumours of Brain, Liver, Kidney and Soft-Parts: Expression Profiles Suggest Common Features but Different Entities.. Cancer Genetics, 2014, 207, 448.	0.4	1
67	Tumeur et dÃ©veloppement (TED)Â: un enregistrement national des associations de cancers pÃ©diatriques et de pathologies malformatives. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2014, 2, 70-77.	0.1	1
68	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
69	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	1.5	33
70	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
71	Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?. Cancer Genetics, 2014, 207, 384-389.	0.4	29
72	Embryonal tumor with multilayered rosettes: Diagnostic tools update and review of the literature. , 2014, 33, 15-22.		38

#	Article	IF	Citations
73	Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncology, The, 2013, 14, e329-e336.	10.7	94
74	Germline mutations in FGF receptors and medulloblastomas. American Journal of Medical Genetics, Part A, 2013, 161, 382-385.	1.2	5
75	Chromosomes en puzzle, le chromothripsis. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2013, 1, 41-43.	0.1	0
76	MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genetics, 2013, 206, 124-129.	0.4	13
77	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
78	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. European Journal of Human Genetics, 2012, 20, 291-297.	2.8	38
79	PHOX2B Immunolabeling. American Journal of Surgical Pathology, 2012, 36, 1141-1149.	3.7	55
80	Conventional Chondrosarcoma in a Survivor of Rhabdoid Tumor. American Journal of Surgical Pathology, 2012, 36, 1892-1896.	3.7	22
81	Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system. Cancer, 2012, 118, 3812-3821.	4.1	101
82	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
83	Medulloblastomas. Current Opinion in Oncology, 2011, 23, 630-637.	2.4	20
84	Homozygous PTEN deletion in neuroblastoma arising in a child with Cowden syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 1763-1766.	1.2	3
85	Fineâ€needle aspiration of renal and extrarenal rhabdoid tumors. Cancer Cytopathology, 2011, 119, 49-57.	2.4	33
86	Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clinical Cancer Research, 2011, 17, 31-38.	7.0	191
87	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3122-3130.	1.6	142
88	Cholinergic switch associated with morphological differentiation in neuroblastoma. Journal of Pathology, 2009, 219, 463-472.	4.5	26
89	VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the SociÃ©tÃ© FranÃ§aise des Cancers de l'Enfant (SFCE). Pediatric Blood and Cancer, 2009, 52, 585-590.	1.5	36
90	Alagille syndrome and nephroblastoma: Unusual coincidence of two rare disorders. Pediatric Blood and Cancer, 2008, 50, 908-911.	1.5	11

#	Article	IF	Citations
91	Extraâ€renal nonâ€cerebral rhabdoid tumours. Pediatric Blood and Cancer, 2008, 51, 363-368.	1.5	80
92	In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin. Oncogene, 2008, 27, 3066-3071.	5.9	29
93	hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. Journal of Pathology, 2007, 211, 323-330.	4.5	120
94	Les Ã©motions dans la relation de soin : des racines de leur rÃ©pression aux enjeux de leur expression. Ã‰thique & SantÃ©, 2006, 3, 133-137.	0.1	6
95	Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Letters, 2005, 228, 51-58.	7.2	63
96	Germline Mutations of the Pairedâ€“Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma. American Journal of Human Genetics, 2004, 74, 761-764.	6.2	288